Oluwadamilola Ogunyankin
Senior Medical Director Abbvie
Oluwadamilola Ogunyankin, MD, MPH is Senior Medical Director, Safety in Early Oncology Development at AbbVie, where he has spent the past two years leading safety strategy for early‑phase oncology programs. He brings over 15 years of global experience in pharmacovigilance and drug safety across biotech, pharma, and CRO environments. Prior to AbbVie, Oluwadamilola held senior safety leadership roles at Amgen and Bayer, with responsibilities spanning global safety science, benefit–risk evaluation, and regulatory interactions. He began his career at Technical Resources International, progressing to Drug Safety and Pharmacovigilance Team Lead. He holds an MD from the University of Ilorin and an MPH from Benedictine University.
Seminars
- Developing a clinical algorithm for the early detection of ILD using high-resolution CT imaging and pulmonary function tests, to differentiate between early, reversible pneumonitis and progressive fibrosis, enabling timely intervention to prevent Grade 3-5 events
- Correlating serum biomarkers with the onset and severity of ILD in real-world patient cohorts, to validate a non-invasive monitoring tool for early detection, allowing clinicians to intervene before the onset of debilitating symptoms
- Building a multidisciplinary approach involving oncologists, pulmonologists, and radiologists, to establish standardized guidelines for the management of ILD and the criteria for safe re-challenge, improving patient outcomes and preserving the therapeutic option
The disconnect between observed clinical toxicities and preclinical predictions continues to challenge ADC development and patient management. Treatments that appear tolerable in early studies can lead to unexpected adverse events in patients, complicating dosing decisions and long-term care. Join clinicians, clinical pharmacologists, and translational experts as they explore how to integrate clinical data, PK/PD insights, and real-world evidence to better interpret safety signals and inform treatment strategies by:
- Interpreting clinical safety signals to inform treatment decisions, exploring how systematic analysis of patient-level data can support dose modifications, treatment interruptions, and proactive toxicity management in clinical practice
- Leveraging translational and pharmacokinetic insights to contextualize toxicity risk, examining how physiologically based pharmacokinetic modeling and cross-species data can help clinicians anticipate adverse events, understand variability in patient response, and apply trial learnings to real-world populations
- Applying exposure-response relationships to guide dosing in the clinic, discussing how evolving dose optimization strategies, including those aligned with Project Optimus, can move toward individualized dosing approaches that balance efficacy and safety for different patient subgroups
